Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Inconsistent detection of an evolving HIV-1 infection by a popular high-throughput screening assay.

Veater JB, Gardener J, Rogers B, Stephenson I, Tang JW.

J Clin Virol. 2018 Aug;105:88-90. doi: 10.1016/j.jcv.2018.06.007. Epub 2018 Jun 12. No abstract available.

PMID:
29929067
2.

Cost effectiveness of screening for dengue infection in a UK teaching hospital.

Veater J, Wong N, Lai FY, Stephenson I, Wiselka M, Tang JW.

J Infect. 2018 Feb;76(2):214-217. doi: 10.1016/j.jinf.2017.09.006. Epub 2017 Sep 14. No abstract available.

PMID:
28919345
3.

Hypogonadism in the HIV-Infected Man.

Wong N, Levy M, Stephenson I.

Curr Treat Options Infect Dis. 2017;9(1):104-116. doi: 10.1007/s40506-017-0110-3. Epub 2017 Feb 14. Review.

4.

Resource impact of managing suspected Middle East respiratory syndrome patients in a UK teaching hospital.

Veater J, Wong N, Stephenson I, Kirk-Granger H, Baxter LF, Cannon R, Wilson S, Atabani S, Sahota A, Bell D, Wiselka M, Tang JW.

J Hosp Infect. 2017 Mar;95(3):280-285. doi: 10.1016/j.jhin.2016.12.010. Epub 2016 Dec 18.

PMID:
28131646
5.

Measles - A tale of two sisters, vaccine failure, and the resurgence of an old foe.

Ahmed A, Sahota A, Stephenson I, Brown KE, Tang JW.

J Infect. 2017 Mar;74(3):318-320. doi: 10.1016/j.jinf.2016.12.012. Epub 2016 Dec 30. No abstract available.

PMID:
28043825
6.

Latent tuberculosis infection screening and treatment in HIV: insights from evaluation of UK practice.

White HA, Miller RF, Pozniak AL, Lipman MC, Stephenson I, Wiselka MJ, Pareek M.

Thorax. 2017 Feb;72(2):180-182. doi: 10.1136/thoraxjnl-2016-209063. Epub 2016 Oct 14.

PMID:
27742873
7.

Optimising value from the soft re-use of brownfield sites.

Bardos RP, Jones S, Stephenson I, Menger P, Beumer V, Neonato F, Maring L, Ferber U, Track T, Wendler K.

Sci Total Environ. 2016 Sep 1;563-564:769-82. doi: 10.1016/j.scitotenv.2015.12.002. Epub 2015 Dec 31.

PMID:
26746674
8.

Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine.

Puleston R, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I, Myles P, Enstone J, Augustine G, Davis Y, Zambon M, Nicholson K, Nguyen-Van-Tam J.

PLoS One. 2013;8(1):e47448. doi: 10.1371/journal.pone.0047448. Epub 2013 Jan 23.

9.

Differences in the compliance with hospital infection control practices during the 2009 influenza H1N1 pandemic in three countries.

Chor JS, Pada SK, Stephenson I, Goggins WB, Tambyah PA, Medina M, Lee N, Leung TF, Ngai KL, Law SK, Rainer TH, Griffiths S, Chan PK.

J Hosp Infect. 2012 Jun;81(2):98-103. doi: 10.1016/j.jhin.2012.04.003. Epub 2012 May 4.

PMID:
22560251
10.

Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard.

Wood JM, Major D, Heath A, Newman RW, Höschler K, Stephenson I, Clark T, Katz JM, Zambon MC.

Vaccine. 2012 Jan 5;30(2):210-7. doi: 10.1016/j.vaccine.2011.11.019. Epub 2011 Nov 17.

PMID:
22100887
11.

Seasonal influenza vaccination predicts pandemic H1N1 vaccination uptake among healthcare workers in three countries.

Chor JS, Pada SK, Stephenson I, Goggins WB, Tambyah PA, Clarke TW, Medina M, Lee N, Leung TF, Ngai KL, Law SK, Rainer TH, Griffiths S, Chan PK.

Vaccine. 2011 Oct 6;29(43):7364-9. doi: 10.1016/j.vaccine.2011.07.079. Epub 2011 Jul 30.

PMID:
21807048
12.

Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy.

Puleston RL, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I, Myles P, Enstone J, Augustine G, Davis Y, Zambon M, Nicholson KG, Nguyen-Van-Tam JS.

Health Technol Assess. 2010 Dec;14(55):1-82. doi: 10.3310/hta14550-01.

13.

Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009.

Stephenson I, Hayden F, Osterhaus A, Howard W, Pervikov Y, Palkonyay L, Kieny MP.

Vaccine. 2010 May 21;28(23):3875-82. doi: 10.1016/j.vaccine.2010.03.074. Epub 2010 Apr 14.

PMID:
20398616
14.

Enteric fever in a UK regional infectious diseases unit: a 10 year retrospective review.

Clark TW, Daneshvar C, Pareek M, Perera N, Stephenson I.

J Infect. 2010 Feb;60(2):91-8. doi: 10.1016/j.jinf.2009.11.009. Epub 2009 Dec 3. Review.

PMID:
19962402
15.

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, Newman RW, Mischler R, Zambon MC, Stephenson I.

Vaccine. 2009 Dec 10;28(1):171-8. doi: 10.1016/j.vaccine.2009.09.103. Epub 2009 Sep 30.

PMID:
19799843
16.

Reproducibility of serologic assays for influenza virus A (H5N1).

Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, Katz JM, Weir JP, Zambon MC, Wood JM.

Emerg Infect Dis. 2009 Aug;15(8):1252-9. doi: 10.3201/eid1508.081754.

17.

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I.

N Engl J Med. 2009 Dec 17;361(25):2424-35. doi: 10.1056/NEJMoa0907650. Epub 2009 Sep 10.

18.

Influenza control in the 21st century: Optimizing protection of older adults.

Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaño LF, Nichol KL, Puig-Barberà J, Schmitt J, Stephenson I.

Vaccine. 2009 Aug 13;27(37):5043-53. doi: 10.1016/j.vaccine.2009.06.032. Epub 2009 Jun 24. Review.

PMID:
19559118
19.

Influenza A/H1N1 in 2009: a pandemic in evolution.

Clark T, Stephenson I.

Expert Rev Vaccines. 2009 Jul;8(7):819-22. doi: 10.1586/erv.09.54. No abstract available.

PMID:
19538107
20.

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7. doi: 10.1073/pnas.0903181106. Epub 2009 Apr 27.

21.

Moving influenza vaccines forward.

Sambhara S, Stephenson I.

Expert Rev Vaccines. 2009 Apr;8(4):375-7. doi: 10.1586/erv.09.10. No abstract available.

PMID:
19348553
22.

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.

Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, Ellis J, Bermingham A, Nicholson K, Zambon M.

Clin Infect Dis. 2009 Feb 15;48(4):389-96. doi: 10.1086/596311.

PMID:
19133796
23.

Willingness of healthcare workers to accept voluntary stockpiled H5N1 vaccine in advance of pandemic activity.

Pareek M, Clark T, Dillon H, Kumar R, Stephenson I.

Vaccine. 2009 Feb 18;27(8):1242-7. doi: 10.1016/j.vaccine.2008.12.006. Epub 2008 Dec 27.

PMID:
19114078
24.

Identification of Streptococcus gallolyticus subsp. macedonicus as the etiological agent in a case of culture-negative multivalve infective endocarditis by 16S rDNA PCR analysis of resected valvular tissue.

Malkin J, Kimmitt PT, Ou HY, Bhasker PS, Khare M, Deng Z, Stephenson I, Sosnowski AW, Perera N, Rajakumar K.

J Heart Valve Dis. 2008 Sep;17(5):589-92.

PMID:
18980096
25.

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A.

N Engl J Med. 2008 Oct 9;359(15):1631-3. doi: 10.1056/NEJMc0805274. No abstract available.

26.

Antiviral treatment and prevention of seasonal influenza: a comparative review of recommendations in the European Union.

Stephenson I, Clark TW, Pareek M.

J Clin Virol. 2008 Jul;42(3):244-8. doi: 10.1016/j.jcv.2008.04.001. Epub 2008 May 19.

PMID:
18486541
27.

Influenza vaccination and asthma: current studies and recommendations.

Stephenson I, Nicholson KG.

BioDrugs. 1999 Apr;11(4):223-8.

PMID:
18031132
28.

Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study.

Stephenson I, Das RG, Wood JM, Katz JM.

Vaccine. 2007 May 16;25(20):4056-63. Epub 2007 Feb 27.

PMID:
17412461
29.

Clinical evaluation of vaccines for pandemic influenza H5N1.

Pareek M, Stephenson I.

Br J Hosp Med (Lond). 2007 Feb;68(2):80-4. Review.

PMID:
17370705
30.

Dengue fever in febrile returning travellers to a UK regional infectious diseases unit.

Stephenson I, Roper J, Fraser M, Nicholson K, Wiselka M.

Travel Med Infect Dis. 2003 May;1(2):89-93.

PMID:
17291893
31.

Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.

Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin A, Stephenson I, Szretter K, Cox NJ, Rudenko LG, Klimov A, Katz JM.

Vaccine. 2006 Nov 10;24(44-46):6588-93. Epub 2006 Jun 5.

PMID:
17030078
32.

H5N1 vaccines: how prepared are we for a pandemic?

Stephenson I.

Lancet. 2006 Sep 16;368(9540):965-6. No abstract available.

PMID:
16980092
33.

Use of neuraminidase inhibitors to combat pandemic influenza.

Democratis J, Pareek M, Stephenson I.

J Antimicrob Chemother. 2006 Nov;58(5):911-5. Epub 2006 Sep 6.

PMID:
16956904
34.

Development of vaccines against influenza H5.

Stephenson I, Gust I, Pervikov Y, Kieny MP.

Lancet Infect Dis. 2006 Aug;6(8):458-60. No abstract available.

PMID:
16870521
35.

Influenza: current threat from avian influenza.

Stephenson I, Democratis J.

Br Med Bull. 2006 May 1;75-76:63-80. Print 2005. Review.

PMID:
16651383
36.

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG.

J Virol. 2006 May;80(10):4962-70.

37.

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S.

Lancet. 2006 Feb 11;367(9509):475-81.

38.

Development and evaluation of influenza pandemic vaccines.

Stephenson I, Gust I, Kieny MP, Pervikov Y.

Lancet Infect Dis. 2006 Feb;6(2):71-2. No abstract available.

PMID:
16439326
39.

Disseminated Sporothix schenckii in a patient with AIDS.

Hardman S, Stephenson I, Jenkins DR, Wiselka MJ, Johnson EM.

J Infect. 2005 Oct;51(3):e73-7. Review.

PMID:
16230207
40.

Transmission of equine influenza virus to dogs.

Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, Chen L, Smith C, Hill RC, Ferro P, Pompey J, Bright RA, Medina MJ, Johnson CM, Olsen CW, Cox NJ, Klimov AI, Katz JM, Donis RO.

Science. 2005 Oct 21;310(5747):482-5. Epub 2005 Sep 26.

41.

Are we ready for pandemic influenza H5N1?

Stephenson I.

Expert Rev Vaccines. 2005 Apr;4(2):151-5. Review.

PMID:
15889987
42.

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM.

J Infect Dis. 2005 Apr 15;191(8):1210-5. Epub 2005 Mar 14.

PMID:
15776364
43.

Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center.

Apisarnthanarak A, Erb S, Stephenson I, Katz JM, Chittaganpitch M, Sangkitporn S, Kitphati R, Thawatsupha P, Waicharoen S, Pinitchai U, Apisarnthanarak P, Fraser VJ, Mundy LM.

Clin Infect Dis. 2005 Jan 15;40(2):e16-8. Epub 2004 Dec 17.

PMID:
15655735
44.

Confronting the avian influenza threat: vaccine development for a potential pandemic.

Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM.

Lancet Infect Dis. 2004 Aug;4(8):499-509. Review.

PMID:
15288823
45.

Buschke-Loewenstein lesion: another possible manifestation of immune restoration inflammatory syndrome?

Moussa R, Stephenson I, Fisk P, Dhar J, Nicholson KG, Wiselka MJ.

AIDS. 2004 May 21;18(8):1221-3. No abstract available.

PMID:
15166544
46.

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.

Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC.

Virus Res. 2004 Jul;103(1-2):91-5.

PMID:
15163495
47.

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.

Stephenson I, Nicholson KG, Glück R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC.

Lancet. 2003 Dec 13;362(9400):1959-66.

PMID:
14683655
48.

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

Stephenson I, Wood JM, Nicholson KG, Zambon MC.

J Med Virol. 2003 Jul;70(3):391-8.

PMID:
12767002
49.

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M.

Vaccine. 2003 Apr 2;21(15):1687-93.

PMID:
12639491
50.

Experience with the clinical development of influenza vaccines for potential pandemics.

Wood JM, Nicholson KG, Stephenson I, Zambon M, Newman RW, Major DL, Podda A.

Med Microbiol Immunol. 2002 Dec;191(3-4):197-201. Epub 2002 Sep 11.

PMID:
12458360

Supplemental Content

Loading ...
Support Center